News
NURO
3.570
+1.71%
0.060
Weekly Report: what happened at NURO last week (0408-0412)?
Weekly Report · 3d ago
Weekly Report: what happened at NURO last week (0401-0405)?
Weekly Report · 04/08 11:28
Weekly Report: what happened at NURO last week (0325-0329)?
Weekly Report · 04/01 11:25
Weekly Report: what happened at NURO last week (0318-0322)?
Weekly Report · 03/25 11:28
Weekly Report: what happened at NURO last week (0311-0315)?
Weekly Report · 03/18 11:26
NeuroMetrix Announces That Over 2000 Patients With Fibromyalgia Have Been Prescribed Quell Fibromyalgia
Over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in December 2022. The device is a transcutaneous electrical nerve stimulation device indicated to reduce the symptoms of fibromyalgia in adults with high pain sensitivity. NeuroMetrix says the company is pleased with the positive response to the product.
Benzinga · 03/13 13:08
Weekly Report: what happened at NURO last week (0304-0308)?
Weekly Report · 03/11 11:23
Echo Lake Capital Calls For The Liquidation Of Neurometrix, Inc. "Notes Tremendous Destruction Of Shareholder Value Under Co's Leadership; Sees No Reason For Co To Remain Public"
Ephraim Fields of Echo Lake Capital wrote a letter to the Board of Directors of Neurometrix, Inc. He believes the company should immediately liquidate because its stock price is trading significantly below its net cash per share. Notes tremendous destruction of shareholder value under company's leadership. Sees no reason for company to remain public.
Benzinga · 03/04 13:08
Weekly Report: what happened at NURO last week (0226-0301)?
Weekly Report · 03/04 11:26
MSTR, NNOX and CAN are among pre market gainers
MSTR, NURO, BETS, EYEN, AQST, CAN, NNOX and CAN are among pre market gainers. Incannex Healthcare announces positive topline results from a clinical trial of psilocybin in anxiety disorder. Bit Brother, Beyond Meat and Beyond Meat are among the other stocks on the move.
Seeking Alpha · 02/28 13:29
Weekly Report: what happened at NURO last week (0219-0223)?
Weekly Report · 02/26 11:40
Press Release: NeuroMetrix Reports Q4 and Full -2-
Dow Jones · 02/22 12:00
Press Release: NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights
NeuroMetrix reports financial and business highlights for the quarter and full year ended December 31, 2023. The Company's mission is to reduce the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices. Quell Fibromyalgia growth accelerated in Q4 2023 and the Company achieved FDA breakthrough device designation for chemotherapy induced peripheral neuropathy.
Dow Jones · 02/22 12:00
Notable earnings before Thursday's open
Major earnings expected before the bell on Thursday include Dominion Energy (D) and Newmont (NEM) Other major earnings slated for release before Thursday's open include: Old Dominion Energy, Iron Mountain, Newmont and Nikola. The company will report its fourth quarter and full year earnings before the open.
Seeking Alpha · 02/21 14:42
NeuroMetrix 13G Filing Shows RS Fund LP Reported A 14.4% Stake In The Co As Of February 13, 2024
Benzinga · 02/20 19:58
Weekly Report: what happened at NURO last week (0212-0216)?
Weekly Report · 02/19 11:43
NeuroMetrix Plans Strategic Options To Promote Growth, Maximize Shareholder Value; Stock Drops
NASDAQ · 02/13 15:32
NeuroMetrix announces review of strategic options for business growth
NeuroMetrix, Inc. Announces review of strategic options for business growth. The company plans to consider a wide range of options to promote growth of its neurodiagnostic businesses. Healthcare NeuroMetrix announced a process to review strategic options to maximize shareholder value for the company.
Seeking Alpha · 02/13 14:22
NeuroMetrix Announces Review Of Strategic Options To Promote Growth Of Its Quell Neuromodulation And DPNCheck Neurodiagnostic Businesses And To Maximize Shareholder Value
NeuroMetrix, Inc. Plans to review strategic options to promote growth of its neuromodulation and neurodiagnostic businesses. The Company plans to consider a wide range of options to maximize shareholder value. The company is focused on reducing the impact of neurological disorders and pain syndromes.
Benzinga · 02/13 14:03
Weekly Report: what happened at NURO last week (0205-0209)?
Weekly Report · 02/12 11:31
More
Webull provides a variety of real-time NURO stock news. You can receive the latest news about Neurometrix Inc through multiple platforms. This information may help you make smarter investment decisions.
About NURO
NeuroMetrix, Inc. is a commercial-stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The Company has two commercial brands. Quell is a wearable neuromodulation platform. DPNCheck is a point-of-care screening test for peripheral neuropathy. It operates two product categories: Diagnostic technology and Therapeutic technology. Diagnostic technology product category is engaged in point-of-care peripheral neuropathy assessment. Therapeutic technology product category is engaged in wearable neuromodulation for chronic pain syndromes. Its patients control and personalize the technology via a mobile phone application, and their utilization and certain clinical metrics may be tracked in the Quell Health Cloud.